Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | CCR2 | P41597 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377319 | 1.00 | LMNA (0.47) | LMNAARHCAR3HCAR2KDM1A | |
| SCHEMBL29949282 | 1.00 | LMNA (0.47) | LMNAARHCAR3HCAR2KDM1A | |
| SCHEMBL377317 | 1.00 | LMNA (0.47) | LMNAARHCAR3HCAR2KDM1A | |
| SCHEMBL17437612 | 0.84 | LMNA (0.44) | LMNACCR2 | |
| SCHEMBL543065 | 0.81 | MEN1 (0.48) | LMNASCN9A | |
| SCHEMBL25399396 | 0.78 | ADAM17 (0.41) | ARHCAR3HCAR2KDM1A | |
| SCHEMBL6099453 | 0.78 | LMNA (0.51) | LMNAHCAR2 | |
| SCHEMBL1172865 | 0.76 | LMNA (0.50) | LMNAHCAR3HCAR2 | |
| SCHEMBL29949390 | 0.76 | LMNA (0.50) | LMNAHCAR3HCAR2 | |
| SCHEMBL25400175 | 0.76 | LMNA (0.50) | LMNAHCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408754-B1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF THE VASOPRESSIN RECEPTOR FOR THE TREATMENT OF CARDIAC INSUFFICIENCY | BAYER IP GMBH (DE) | 2013-10-09 | — | — | EP | disclosed |
| EP-2408754-B1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF THE VASOPRESSIN RECEPTOR FOR THE TREATMENT OF CARDIAC INSUFFICIENCY | BAYER IP GMBH (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-20120053218-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053218-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053218-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053218-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | AVPR2, AVPR1B, AVPR1A | LMNA 1542/4885AR 2120/4885HCAR3 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.